Activity of ICI 195,739, a new oral triazole, compared with that of ketoconazole in the therapy of experimental murine blastomycosis
- 1 April 1989
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 33 (4), 573-575
- https://doi.org/10.1128/aac.33.4.573
Abstract
ICI 195,739, a novel orally active triazole, proved 50 times as potent as ketoconazole, produced a clinical cure, and completely eradicated residual infection in a murine model of pulmonary blastomycosis. No other previously tested azole has shown similar activity. Fungicidal activity against Blastomyces dermatitidis was seen in vitro at concentrations 1/40 of those achieved in serum with protective doses.This publication has 7 references indexed in Scilit:
- Treatment of Mycoses with ItraconazoleAnnals of the New York Academy of Sciences, 1988
- Activity of ICI 195,739—a Novel, Orally Active Bistriazole—in Rodent Models of Fungal and Protozoal InfectionsAnnals of the New York Academy of Sciences, 1988
- Activities of the modified polyene N-D-ornithyl amphotericin methyl ester and the azoles ICI 153066, Bay n 7133, and Bay l 9139 compared with those of amphotericin B and ketoconazole in the therapy of experimental blastomycosisAntimicrobial Agents and Chemotherapy, 1985
- Experience with ketoconazole in three major manifestations of progressive coccidioidomycosisThe American Journal of Medicine, 1983
- Treatment of Systemic Mycoses with Ketoconazole: Emphasis on Toxicity and Clinical Response in 52 PatientsAnnals of Internal Medicine, 1983
- MOUSE MODEL OF PULMONARY BLASTOMYCOSIS - UTILITY, SIMPLICITY, AND QUANTITATIVE PARAMETERSPublished by Elsevier ,1978
- Antimicrobial Susceptibility Testing of Yeasts: a Turbidimetric Technique Independent of Inoculum SizeAntimicrobial Agents and Chemotherapy, 1976